Skip to main content

ILYM21090 / MB106-CD20-001 / Reagan

Basic Study Information

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

Location: University of Rochester Medical Center

Lead Researcher (Principal Investigator)

Lead Researcher:  Patrick Reagan

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search